ITGB1 Antibodies

Structure of ITGB1

ITGB1 is a transmembrane glycoprotein with a molecular weight of approximately 97 kDa. Its molecular weight is relatively conserved among different species, but it can fluctuate slightly through differential glycosylation and other means. The following are the molecular weight references for some species:

This protein is composed of approximately 798 amino acids, forming a typical structure that includes the extracellular domain, transmembrane region and intracellular tail region. Its extracellular domain contains multiple repetitive domains (such as the β-propeller structure), which are responsible for recognizing extracellular matrix proteins (such as fibronectin and laminin) and mediating cell adhesion. The intracellular domain interacts with the cytoskeleton through conjunctive proteins such as talin and vinculin, transmitting mechanical signals into the cell and thereby regulating the processes of cell migration, proliferation and differentiation.

Fig. 1 ITGB1 and physiological function, benign disease.¹

Key structural properties of ITGB1:

• Extracellular domain beta propeller structure formation, responsible for identifying ligands ecms
• Across the membrane area keep anchor protein on the cell membrane
• Intracellular tail region contains NPxY motif, such as mediated cytoskeleton connection

Functions of ITGB1

The main function of ITGB1 is to mediate the adhesion between cells and extracellular matrix and bidirectional signal transduction. In addition, it is also involved in regulating a variety of key cellular physiological processes.

The affinity of ITGB1 for ligands is dynamically regulated by conformational changes (low, medium and high affinity states), a characteristic that enables it to precisely respond to microenvironmental changes and complete complex biological regulation.

Applications of ITGB1 and ITGB1 Antibody in Literature

1. Li, Yuexian, et al. "ITGB1 enhances the radioresistance of human non-small cell lung cancer cells by modulating the DNA damage response and YAP1-induced epithelial-mesenchymal transition." International journal of biological sciences 17.2 (2021): 635. https://doi.org/10.7150/ijbs.52319

Studies have shown that ITGB1 is highly expressed in non-small cell lung cancer cells and enhances radiation resistance by promoting DNA repair and YAP1-induced epithelial-mesenchymal transition, suggesting it as a potential therapeutic target for reversing radiotherapy tolerance.

2. Sun, Rui, et al. "ALKBH5 activates FAK signaling through m6A demethylation in ITGB1 mRNA and enhances tumor-associated lymphangiogenesis and lymph node metastasis in ovarian cancer." Theranostics 13.2 (2023): 833. https://doi.org/10.7150/thno.77441

Research has revealed that ALKBH5 promotes lymphangiogenesis and lymph node metastasis of ovarian cancer by reducing the m6A modification of ITGB1, enhancing its expression and activating the FAK/Src pathway. This signaling axis provides a new target for anti-metastasis therapy.

3. Yu-Jiao, Zhou, et al. "RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling." Journal of Experimental and Clinical Cancer Research 43 (2024): 1. https://doi.org/10.1186/s13046-023-02929-1 

Research reveals that RPS7 enhances the expression of LOXL2 mRNA by stabilizing it, thereby maintaining the stability of ITGB1 protein and activating the downstream FAK/SRC pathway, ultimately promoting the metastasis of hepatocellular carcinoma. This axis provides a new target for anti-metastasis treatment.

4. Gu, Wenchao, et al. "ITGB1 as a prognostic biomarker correlated with immune suppression in gastric cancer." Cancer Medicine 12.2 (2023): 1520-1531. https://doi.org/10.1002/cam4.5042 

Studies have shown that the high expression of ITGB1 in gastric cancer is associated with tumor invasion, advanced stage and poor prognosis. It activates the Wnt/β-catenin pathway and mediates immunosuppression, suggesting that it can serve as a prognostic marker and a potential predictor of the efficacy of immunotherapy.

5. Zhu, Xingyu, et al. "ITGB1-mediated molecular landscape and cuproptosis phenotype induced the worse prognosis in diffuse gastric cancer." Frontiers in Oncology 13 (2023): 1115510. https://doi.org/10.3389/fonc.2023.1115510 

Studies have shown that in diffuse gastric cancer, high expression of ITGB1 predicts a poor prognosis. It promotes tumor growth by regulating the ROCK1/PKA/AKT signaling pathway and inhibits the copper death metabolic pathway, suggesting that ITGB1 is a potential therapeutic target.

Creative Biolabs: ITGB1 Antibodies for Research

Creative Biolabs specializes in the production of high-quality ITGB1 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom ITGB1 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our ITGB1 antibodies, custom preparations, or technical support, contact us at email.